Dogwood Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $21.9M | $3.5M | $1.7M | $8.1M | $10.8M |
| Operating expenses | $28.0M | $12.2M | $5.4M | $12.3M | $15.6M |
| Operating income | -$28.0M | -$12.2M | -$5.4M | -$12.3M | -$15.6M |
| Pretax income | -$34.0M | -$12.4M | -$5.3M | -$12.2M | -$16.0M |
| Income tax expense | $221,096 | -$503 | — | — | — |
| Net income | -$34.3M | -$12.3M | -$5.3M | -$12.2M | -$16.0M |
| Balance Sheet | |||||
| Cash and equivalents | $6.5M | $14.8M | $3.3M | $7.0M | $14.0M |
| Current assets | $8.4M | $16.5M | $4.2M | $8.4M | $15.8M |
| Total assets | $90.2M | $94.3M | $4.2M | $8.4M | $15.8M |
| Current liabilities | $3.1M | $3.2M | $358,548 | $1.0M | $1.3M |
| Total liabilities | $15.3M | $30.0M | $358,548 | $1.0M | $1.3M |
| Stockholders' equity | $74.9M | -$10.1M | $3.8M | $7.3M | $14.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.6M | -$8.8M | -$4.9M | -$11.5M | -$15.7M |
| Depreciation and amortization | $2,063 | $12,177 | — | — | — |
| Stock-based compensation | $355,642 | $476,021 | $619,972 | $582,659 | $322,881 |
| Impairments | $0 | $0 | — | — | — |
Shares outstanding 33.6M · Free float 26.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.